© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 3, 190-197,
February 5, 2003
© 2003 Oxford University Press
REVIEW |
Adjuvant Breast Cancer Treatment and Cognitive Function: Current Knowledge and Research Directions
Affiliations of authors: K.-A. Phillips, Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, St. Andrew's Place, East Melbourne, Victoria, Australia; J. Bernhard, International Breast Cancer Study Group, Coordinating Center, Bern, Switzerland.
Correspondence to: Kelly-Anne Phillips, M.B.B.S., M.D., F.R.A.C.P., Department of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Locked Bag No. 1, A'Beckett St., Victoria, 8006, Australia (e-mail: Kelly.Phillips{at}petermac.org).
Evidence is mounting that potentially curative systemic adjuvant therapy for early-stage breast cancer may result in cognitive impairment. Five published studies have investigated cognitive function in this setting, and the consistent results of all five studies suggest an adverse effect of adjuvant chemotherapy. These studies are reviewed with particular attention to their methodologic limitations. For example, all five studies used cross-sectional designs, none controlled for possible confounding hormonal factors, and three examined patients who had not received a uniform chemotherapy regimen. The potential roles of chemotherapy-induced menopause and of adjuvant hormonal therapy in cognitive impairment are also discussed. Priorities for future research include confirmation of an effect of adjuvant chemotherapy in a study with a longitudinal design, closer examination of the potential contribution of hormonal factors, and similar studies on the effect of adjuvant therapy on cognitive function in other cancer types. If an effect of systemic adjuvant therapy on cognitive function is confirmed, such an effect will have implications for informed consent. It may also result in incorporation of objective measures of cognition in clinical trials of adjuvant therapy and in the investigation of preventive interventions that might minimize the impact of cognitive dysfunction after cancer treatment.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Maruff, E. Thomas, L. Cysique, B. Brew, A. Collie, P. Snyder, and R. H. Pietrzak Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex Arch Clin Neuropsychol, March 25, 2009; (2009) acp010v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Magai, N. S. Consedine, B. A. Adjei, D. Hershman, and A. Neugut Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention Health Educ Behav, December 1, 2008; 35(6): 835 - 854. [Abstract] [PDF]
|
|
|
|
 |
|
 R. J. Ferguson, B. C. McDonald, A. J. Saykin, and T. A. Ahles Brain Structure and Function Differences in Monozygotic Twins: Possible Effects of Breast Cancer Chemotherapy J. Clin. Oncol., September 1, 2007; 25(25): 3866 - 3870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vardy, S. Rourke, and I. F. Tannock Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research J. Clin. Oncol., June 10, 2007; 25(17): 2455 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kohli, J. J. Griggs, J. A. Roscoe, P. Jean-Pierre, C. Bole, K. M. Mustian, R. Hill, K. Smith, H. Gross, and G. R. Morrow Self-Reported Cognitive Impairment in Patients With Cancer J. Oncol. Pract, March 1, 2007; 3(2): 54 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Johnston, C. Yang, K.-K. Hui, B. Xiao, X. Li, and A. Rusiewicz Acupuncture for Chemotherapy-Associated Cognitive Dysfunction: A Hypothesis-Generating Literature Review to Inform Clinical Advice Integr Cancer Ther, March 1, 2007; 6(1): 36 - 41. [Abstract] [PDF]
|
|
|
|
 |
|
 G. D. Lee, D. L. Longo, Y. Wang, J. M. Rifkind, L. Abdul-Raman, J. A. Mamczarz, K. B. Duffy, E. L. Spangler, D. D. Taub, M. P. Mattson, et al. Transient Improvement in Cognitive Function and Synaptic Plasticity in Rats Following Cancer Chemotherapy Clin. Cancer Res., January 1, 2006; 12(1): 198 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. G. M. Fan, N. Houede-Tchen, Q.-L. Yi, I. Chemerynsky, F. P. Downie, K. Sabate, and I. F. Tannock Fatigue, Menopausal Symptoms, and Cognitive Function in Women After Adjuvant Chemotherapy for Breast Cancer: 1- and 2-Year Follow-Up of a Prospective Controlled Study J. Clin. Oncol., November 1, 2005; 23(31): 8025 - 8032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis Effects of estrogen deprivation due to breast cancer treatment Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. F. Tannock, T. A. Ahles, P. A. Ganz, and F. S. van Dam Cognitive Impairment Associated With Chemotherapy for Cancer: Report of a Workshop J. Clin. Oncol., June 1, 2004; 22(11): 2233 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Ganz, L. Kwan, A. L. Stanton, J. L. Krupnick, J. H. Rowland, B. E. Meyerowitz, J. E. Bower, and T. R. Belin Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized Trial J Natl Cancer Inst, March 3, 2004; 96(5): 376 - 387. [Abstract] [Full Text] [PDF]
|
|